Trials / Recruiting
RecruitingNCT07371403
MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia
MB-CART19.1 in Patients With Relapsed/Refractory CD19-positive B Cell Acute Lymphoblastic Leukemia: A Feasibility Study
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- King Hussein Cancer Center · Academic / Other
- Sex
- All
- Age
- 1 Year
- Healthy volunteers
- Not accepted
Summary
Single-arm, prospective, open-label feasibility study evaluating the technical and operational feasibility of manufacturing autologous CD19-directed CAR-T cells (MB-CART19.1) at the point of care for the treatment of relapsed or refractory B-ALL in pediatric and adult patients.
Conditions
- Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia Recurrent
- Acute Lymphoblastic Leukemia Refractory
- Acute Lymphoblastic Leukemia Not Having Achieved Remission
- Acute Lymphoblastic Leukemia With Failed Remission
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | MB-CART19.1 | All participants will undergo leukapheresis for collection of autologous T cells, which will then be manufactured into MB-CART19.1 on-site using CliniMACS Prodigy platform. Successfully manufactured MB-CART19.1 products will be infused back to the patient following a lymphodepleting chemotherapy regimen. |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2029-01-01
- Completion
- 2029-01-01
- First posted
- 2026-01-27
- Last updated
- 2026-03-25
Locations
1 site across 1 country: Jordan
Source: ClinicalTrials.gov record NCT07371403. Inclusion in this directory is not an endorsement.